Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Operating Leases (2019 - 2025)

Sangamo Therapeutics has reported Operating Leases over the past 7 years, most recently at $25.1 million for Q4 2025.

  • Quarterly results put Operating Leases at $25.1 million for Q4 2025, down 4.42% from a year ago — trailing twelve months through Dec 2025 was $25.1 million (down 4.42% YoY), and the annual figure for FY2025 was $25.1 million, down 4.42%.
  • Operating Leases for Q4 2025 was $25.1 million at Sangamo Therapeutics, down from $25.4 million in the prior quarter.
  • Over the last five years, Operating Leases for SGMO hit a ceiling of $44.1 million in Q4 2021 and a floor of $23.5 million in Q2 2025.
  • Median Operating Leases over the past 5 years was $35.5 million (2021), compared with a mean of $33.7 million.
  • Biggest five-year swings in Operating Leases: increased 14.74% in 2021 and later decreased 21.67% in 2024.
  • Sangamo Therapeutics' Operating Leases stood at $44.1 million in 2021, then dropped by 11.51% to $39.0 million in 2022, then fell by 14.03% to $33.5 million in 2023, then decreased by 21.67% to $26.3 million in 2024, then dropped by 4.42% to $25.1 million in 2025.
  • The last three reported values for Operating Leases were $25.1 million (Q4 2025), $25.4 million (Q3 2025), and $23.5 million (Q2 2025) per Business Quant data.